Skin conditions research

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SCD-044 IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS

This study is testing a new medicine, SCD-044, for people with moderate to severe eczema (atopic dermatitis). Researchers want to see if different doses of this medicine are safe and help improve eczema symptoms by a lot.

A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis

This study is looking into a new medicine called Nemolizumab for children aged 2 to 11 who have moderate to severe eczema. It aims to see how safe the medicine is, how well it works, and how the body handles it. It's an important step in finding new ways to help children with eczema.

An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczema

This study is looking into a new treatment called Dupilumab (Dupixent) for people with a type of eczema called nummular eczema. Researchers want to see if it makes their skin better and improves their quality of life. It's an important step in finding new ways to help manage this skin condition.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

This study is looking at a new medicine called BI 765250 for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe, how the body handles it, and if it helps improve psoriasis, compared to a dummy treatment.

An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates

This study looks at how a new medicine, amlitelimab, affects other common medicines in the body. It's for adults with eczema and helps us understand how different drugs work together safely. This is an early-stage study to gather important information.

AliCsa; Efficacy of oral alitretinoin versus oral cyclosporine in patients with moderate to very severe hand eczema. A randomized prospective open-label trial with blinded outcome assessment

This study compares two existing medicines, alitretinoin and ciclosporin, for treating moderate to severe hand eczema. Researchers want to see which one works better and has fewer side effects over 24 weeks. It's for adults with this skin condition.

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1)

This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. It compares ESK-001 to a common treatment (Otezla) and a dummy pill (placebo) to see how well it works and if it's safe.

A Study Evaluating APG777 in Atopic Dermatitis

This study is looking at a new medicine called APG777 for moderate to severe eczema (atopic dermatitis). Researchers want to see if it's safe and helps improve symptoms compared to a dummy medicine. It involves testing different strengths of APG777.

A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema

This study looks at how well a moisturiser called Doublebase Once works for people with eczema. Participants, including children and adults, will use it daily for four weeks instead of their usual cream. Researchers will check skin health and gather feedback.

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

This study is for people who have already taken part in certain Incyte povorcitinib trials for Hidradenitis Suppurativa (HS) and found the treatment helpful. It allows them to continue receiving the study drug if their doctor agrees it's safe and beneficial.

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

This study looks at a new treatment called amlitelimab for moderate to severe eczema in people aged 12 and older. It aims to understand its safety and how well it works over a long time. It involves regular visits and lasts several years.

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

This study is testing a new medicine called povorcitinib for people with a type of vitiligo called nonsegmental vitiligo. Researchers want to see if it's safe and helps improve the skin patches. It's a Phase 3 trial, meaning it's a later stage of research.

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

This study looks at how safe and effective a new medicine, Sonelokimab, is for a long time in people with moderate to severe Hidradenitis Suppurativa. It's for those who have already been in similar Sonelokimab studies.

A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.

A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema

This study looks at how well a moisturiser called Doublebase Once works for people with eczema. Participants, including children and adults, will use it daily for four weeks instead of their usual cream. Researchers will check skin health and gather feedback.

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

This study is looking at a new medicine called nemolizumab for people with moderate to severe eczema. It aims to understand how safe and effective the medicine is over a long period. Participants would have been in a previous nemolizumab study.

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

This study is looking into new ways to treat moderate to severe atopic dermatitis (eczema). It will test a new medicine called GHZ339 to see if it's safe and effective for adults. We want to find better options for people living with this skin condition.

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

This study looks at a new treatment for vitiligo, a condition where patches of skin lose their colour. It compares a special implant (afamelanotide) combined with light therapy (NB-UVB) against light therapy alone, to see how well they work and if they are safe.

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

This study is testing a new medicine, remibrutinib, for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). Researchers want to see if it's safe and effective compared to a dummy pill.

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

This study looks at how well a new medicine, nemolizumab (Nemluvio®), works for teenagers and adults with moderate to severe eczema in real-life settings. Doctors will check progress, and patients will share how they feel about their symptoms over about 12 months.

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

This study looks at how well a new medicine, lebrikizumab, works and if it's safe for teenagers and adults with moderate to severe eczema. It wants to see if the medicine can improve skin symptoms over 24 weeks.

A Study With CIT-013 in HS Patients

This study is testing a new medicine called CIT-013 for adults with Hidradenitis Suppurativa (HS), a skin condition. Researchers want to see if CIT-013 helps reduce HS symptoms and if it's safe. It's a Phase 2 trial comparing different doses of CIT-013 to a dummy medicine.

HIPPOCRATES Prospective Observational Study

This study aims to find out why some people with psoriasis get psoriatic arthritis. We'll use questionnaires and some blood samples to help identify those at risk. Our goal is to one day prevent arthritis from developing.

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

This study looks at a new medicine called Povorcitinib for moderate to severe hidradenitis suppurativa (HS). It's for people who have already finished an earlier study. We want to see how safe and effective it is over a longer time.

Characterisation of Skin Microstructure Under Normal and Atrophied States

This study looks at how healthy skin is structured and how it changes in people with eczema who have used steroid creams for a long time. It uses a special light scan to see inside the skin without needles, aiming to understand the effects of treatments better.

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

This study looks at a new drug, upadacitinib, for moderate to severe Hidradenitis Suppurativa (HS). It's for adults and teenagers whose HS hasn't improved with other treatments. We'll check if it's safe and helps reduce HS symptoms.

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

This study is looking at a new medicine called deucravacitinib for children and teenagers aged 4 to 17 with moderate to severe plaque psoriasis. It aims to understand how much medicine is needed, if it works, and if it's safe to use.

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

This study is looking into a new treatment called JNJ-77242113 for moderate to severe plaque psoriasis in teenagers and adults. We want to see how well it works to improve skin symptoms. It's a Phase 3 trial, meaning it's a key step in testing this potential new medicine.

Vitiligo Registry for Adults and Children in the UK

This study is gathering information on people in the UK with vitiligo, both adults and children. It's creating a big database to better understand the condition, how treatments work, and how safe they are, as there isn't one like this right now.

Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial

This study looks at whether a daily probiotic drink can help women aged 40-60 with skin issues like eczema or rosacea. We want to see if it can reduce inflammation and improve their immune system during menopause.

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

This study looks at the long-term effects of a new medicine, rocatinlimab, for teenagers and adults with moderate to severe eczema. It checks how safe and well-tolerated the medicine is, and if it continues to help over time.

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

This study is for people with moderate to severe Hidradenitis Suppurativa who have already been treated with Secukinumab in previous studies. It looks at whether continuing this medicine or stopping it works best long-term, and how safe it is.

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

This study is testing a new medicine, Amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It's looking at how well different doses work and if they're safe, compared to stopping treatment.

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

This study looks at new treatments for moderate to severe eczema (atopic dermatitis). It checks how well a drug called Lutikizumab works, either alone or with other treatments, and if it's safe. Participants will get injections and have regular check-ups.

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

This study is testing a new oral medication, SYX-5219, for moderate to severe eczema (atopic dermatitis). It aims to check the drug's safety, how well it's tolerated, and how it moves through the body in both healthy people and those with eczema.

SEquential Treatment of PSoriasis With Biologics

This study looks at how well different psoriasis treatments called biologics work when people try several in a row. It uses existing health records to understand if these treatments become less effective over time. No extra appointments are needed for this research.

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

This study is testing a new medicine, baricitinib, for children and teenagers aged 2 to 17 with moderate to severe eczema. Researchers want to see if it's safe and helps improve their skin compared to a dummy pill or usual treatments.

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.

A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

This study looks at how skin conditions like alopecia areata, vitiligo, and hidradenitis suppurativa affect daily life for teenagers and adults. Researchers want to understand the challenges these conditions bring to people all over the world.

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

This study looks at a new medicine called amlitelimab for people aged 12 and over with moderate-to-severe eczema. These individuals haven't responded well to other common eczema treatments. Researchers want to see if amlitelimab is safe and helps improve their skin when used with their usual steroid creams.